| Michael Ashley Leroy, MD | |
|
1101 Medical Center Blvd, Marrero, LA 70072-3147 | |
| (504) 349-1387 | |
| Not Available |
| Full Name | Michael Ashley Leroy |
|---|---|
| Gender | Male |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 1101 Medical Center Blvd, Marrero, Louisiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336373422 | NPI | - | NPPES |
| 1882879 | Medicaid | LA |
| Entity Name | Louisiana State University School Of Medicine In New Orleans Faculty G |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477582526 PECOS PAC ID: 0244136448 Enrollment ID: O20031209000661 |
News Archive
Thomson CompuMark, the global leader in trademark searching and brand protection solutions and part of Thomson Reuters, today announced the launch of Global Pharmaceutical Search, a new service providing targeted, global trademark intelligence in a single online report.
Traditionally, the theory driving discussions on the high cost of health care in the United States has been that there is enormous waste in the system, taking the form of excess utilization of care. From that theory it follows that methods of controlling the growth of health spending should focus on ways to reduce the use of unnecessary or only marginally beneficial health care.
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the likelihood of recurrence of breast cancer following surgery and initial treatment.
The number of diabetics worldwide is exploding. In response, the largest study of its kind to date is set to investigate type-2 diabetes prevention through diet, exercise and lifestyle. Eight EU nations, along with New Zealand, Australia and Canada, will participate in an EU-funded project headed by University of Copenhagen researchers.
› Verified 7 days ago
| Entity Name | The Delta Pathology Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548258973 PECOS PAC ID: 4789639089 Enrollment ID: O20050321000139 |
News Archive
Thomson CompuMark, the global leader in trademark searching and brand protection solutions and part of Thomson Reuters, today announced the launch of Global Pharmaceutical Search, a new service providing targeted, global trademark intelligence in a single online report.
Traditionally, the theory driving discussions on the high cost of health care in the United States has been that there is enormous waste in the system, taking the form of excess utilization of care. From that theory it follows that methods of controlling the growth of health spending should focus on ways to reduce the use of unnecessary or only marginally beneficial health care.
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the likelihood of recurrence of breast cancer following surgery and initial treatment.
The number of diabetics worldwide is exploding. In response, the largest study of its kind to date is set to investigate type-2 diabetes prevention through diet, exercise and lifestyle. Eight EU nations, along with New Zealand, Australia and Canada, will participate in an EU-funded project headed by University of Copenhagen researchers.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Ashley Leroy, MD Po Box 3780, Tupelo, MS 38803-3780 Ph: (318) 841-9526 | Michael Ashley Leroy, MD 1101 Medical Center Blvd, Marrero, LA 70072-3147 Ph: (504) 349-1387 |
News Archive
Thomson CompuMark, the global leader in trademark searching and brand protection solutions and part of Thomson Reuters, today announced the launch of Global Pharmaceutical Search, a new service providing targeted, global trademark intelligence in a single online report.
Traditionally, the theory driving discussions on the high cost of health care in the United States has been that there is enormous waste in the system, taking the form of excess utilization of care. From that theory it follows that methods of controlling the growth of health spending should focus on ways to reduce the use of unnecessary or only marginally beneficial health care.
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the likelihood of recurrence of breast cancer following surgery and initial treatment.
The number of diabetics worldwide is exploding. In response, the largest study of its kind to date is set to investigate type-2 diabetes prevention through diet, exercise and lifestyle. Eight EU nations, along with New Zealand, Australia and Canada, will participate in an EU-funded project headed by University of Copenhagen researchers.
› Verified 7 days ago
Kenneth Barton Farris, MD Pathology Medicare: Medicare Enrolled Practice Location: 1101 Medical Center Blvd, Marrero, LA 70072 Phone: 504-347-5511 | |
James Edward Brown Jr., MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1101 Medical Center Boulevard, Marrero, LA 70072 Phone: 504-347-5511 | |
William Herman Luer, MD Pathology Medicare: Medicare Enrolled Practice Location: 1101 Medical Center Boulevard, Marrero, LA 70072 Phone: 504-349-1415 | |
Michael David Brown, MD Pathology Medicare: Medicare Enrolled Practice Location: 1111 Medical Center Blvd, Suite S-450, Marrero, LA 70072 Phone: 504-349-6401 Fax: 504-349-6444 | |
Dr. Kelley Willis Sherling, MD Pathology Medicare: Medicare Enrolled Practice Location: 1111 Medical Center Blvd., Sutie S-450, Marrero, LA 70072 Phone: 504-349-6401 Fax: 504-349-6444 |